3,5'-bis-1H-indole | 66616-64-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3,5'-bis-1H-indole
• 英文别名: 1H,1'H-3,5'-biindole；3,5'-Diindolyl；1H,1'H-[3,5']biindolyl；3,5'-Bi-1H-indole；3-(1H-indol-5-yl)-1H-indole
• CAS: 66616-64-6
• 化学式: C₁₆H₁₂N₂
• 分子量: 232.285
• InChiKey: PANZQOXPUWEGMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  31.6
• 氢给体数：
  2
• 氢受体数：
  0

反应信息

• 作为产物：
  描述：

  2,2'-Dicarboxy-3,5'-diindolyl 以43%的产率得到
  参考文献：
  名称：

  CYBOPOB N. N.; SAMSONIYA SH. A.; CHILIKIN L. G.; CHIKVAIDZE I. SH.; TURCH+, XIMIYA GETEROTSIKL. SOEDIN., 1978, HO 2, 217-224

  摘要：

  DOI：

文献信息

• Pd/β-cyclodextrin-catalyzed C–H functionalization in water: a greener approach to regioselective arylation of (NH)-indoles with aryl bromides
  作者：Peng Xu、Xin Hong Duan

  DOI：10.1039/d1nj03400f

  日期：——

  A greener and more practical strategy for the site-selective C–H arylation of (NH)-indoles via coupling of (hetero)aryl bromides was developed, in which β-cyclodextrin, acting as both a ligand for Na2PdCl4 and a host for indoles, enables the reactions to occur easily in water. The key advantage of this method is the ingenious merging of aqueous homogeneous catalysis and ligand mediation, leading to

  开发了一种更环保、更实用的策略，用于通过（杂）芳基溴化物的偶联对 (NH)-吲哚进行位点选择性 C-H 芳基化，其中 β-环糊精作为 Na 2 PdCl 4的配体和吲哚的宿主，使反应在水中容易发生。这种方法的关键优势是水相均相催化和配体介导的巧妙融合，导致具有广泛底物范围和官能团耐受性的 C3-芳基吲哚的高度区域选择性形成。此外，区域选择性可以通过改变碱基的性质而从 C3 位切换到 C2 位，而无需使用 ArI 作为底物。
• ArylSulfonamide Based Matrix Metalloprotease Inhibitors
  申请人：Ehrhardt Claus

  公开号：US20120258954A1

  公开（公告）日：2012-10-11

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种式(I)的化合物：该化合物是MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13异常活性所特征的疾病或疾病。因此，式(I)的化合物可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种制药组合物。
• ArylSulfonamide-Based Matrix Metalloprotease Inhibitors
  申请人：EHRHARDT Claus

  公开号：US20150045398A1

  公开（公告）日：2015-02-12

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物(I)：所述化合物是MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13异常活性所特征化的疾病或疾患。因此，化合物(I)可用于治疗由MMP-2、和/或MMP-8、和/或MMP-9、和/或MMP-12和/或MMP-13介导的疾病或疾患。最后，本发明还提供了一种制药组合物。
• ARYLSULFONAMIDE-BASED MATRIX METALLOPROTEASE INHIBITORS
  申请人：Ehrhardt Claus

  公开号：US20110014186A1

  公开（公告）日：2011-01-20

  The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.

  本发明提供了一种化合物(I)的公式：该化合物是MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13的抑制剂，因此可用于治疗由MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13异常活动所表征的疾病或疾病。因此，公式(I)的化合物可用于治疗由MMP-2、MMP-8、MMP-9、MMP-12和/或MMP-13介导的疾病或疾病。最后，本发明还提供了一种制药组合物。
• US8222424B2
  申请人：——

  公开号：US8222424B2

  公开（公告）日：2012-07-17